Phase 3 Heart failure trials recruiting now

All Heart failure trials, every phase

Other phases for Heart failure

Phase 3 Heart failure trials

• A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
  NCT06578078 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 6 locations
• A Danish Pragmatic Randomized Trial of Nutritional Supplements in Heart Failure
  NCT06694727 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
  NCT03394365 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 71 locations
• A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)
  NCT07496372 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1676 locations
• A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
  NCT06056297 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 114 locations
• A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
  NCT06024746 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 140 locations
• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
  NCT06008197 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 356 locations
• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
  NCT06033950 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 176 locations
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 672 locations
• A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07192952 · Phase: Phase 3 · Ages: Up to 18 Years · Sex: All (male and female) · 132 locations
• A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
  NCT07188805 · Phase: Phase 3 · Ages: 6 Months to 17 Years · Sex: All (male and female) · 133 locations
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 588 locations
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 652 locations
• Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients
  NCT06535529 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure
  NCT06783166 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction
  NCT07820410 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction
  NCT06518694 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 295 locations
• CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
  NCT06158698 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
  NCT05873881 · Phase: Phase 3 · Ages: 45 Years and older · Sex: All (male and female) · 1 location
• CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
  NCT06304857 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 3 locations
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1114 locations
• Dapagliflozin for Cardio-renal Protection After ICU Discharge
  NCT07025629 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
  NCT05392764 · Phase: Phase 3 · Ages: 20 Years and older · Sex: All (male and female) · 69 locations
• Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
  NCT05879276 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
  NCT04020263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
  NCT06423599 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
  NCT07038356 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
  NCT05714085 · Phase: Phase 2, Phase 3 · Ages: 29 Days to 17 Years · Sex: All (male and female) · 109 locations
• Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
  NCT06898515 · Phase: Phase 3 · Ages: 22 Years and older · Sex: All (male and female) · 53 locations
• HFrEF Polypill in Sri Lanka RCT
  NCT07569640 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Home-based Cardiac Rehabilitation in Heart Failure
  NCT06349941 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
  NCT07288398 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 282 locations
• MYTHS - MYocarditis THerapy With Steroids
  NCT05150704 · Phase: Phase 3 · Ages: 18 Years to 69 Years · Sex: All (male and female) · 49 locations
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1314 locations
• Medication Withdrawal in Stable HF With Improved LVEF
  NCT07489547 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension
  NCT06405555 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
  NCT06929806 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
  NCT06082063 · Phase: Phase 3 · Ages: 40 Years to 90 Years · Sex: All (male and female) · 2 locations
• Optimising Pacing for Contractility 2
  NCT04201015 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Optimizing HFrEF Patients Using BaroStim and CardioMems
  NCT07399587 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• PREVENTION OF WORSENING RENAL FUNCTION OF INTRAVENUS ALBUMIN IN HEART FAILURE PATIENTS
  NCT06630923 · Phase: Phase 3 · Ages: 18 Years to 95 Years · Sex: All (male and female) · 1 location
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · 957 locations
• Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
  NCT06220032 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
  NCT07687186 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 60 locations
• RECOMMEND Platform Trial
  NCT06526533 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 3 locations
• Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
  NCT04982419 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction
  NCT05553886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
  NCT06955260 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
  NCT06142474 · Phase: Phase 3 · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• Selenium Intervention Registry Randomized Trial in Heart Failure
  NCT07543562 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
  NCT06217302 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 19 locations
• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
  NCT02901184 · Phase: Phase 3 · Ages: 50 Years to 99 Years · Sex: All (male and female) · 78 locations
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
  NCT06736574 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 205 locations
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
  NCT06597019 · Phase: Phase 3 · Ages: 6 Years to 11 Years · Sex: All (male and female) · 66 locations
• Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
  NCT06597006 · Phase: Phase 3 · Ages: 2 Years to 11 Years · Sex: All (male and female) · 19 locations
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 852 locations
• Tailored Exercise Training Study Among Adults With HFpEF
  NCT07223242 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction
  NCT05508035 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients
  NCT06503016 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure
  NCT07008365 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 4 locations
• The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands.
  NCT07234422 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1
  NCT06030843 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
  NCT07221851 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 43 locations
• Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
  NCT07079735 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 2 locations
• Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy
  NCT06128980 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.